2-[3-(propan-2-yl)-1H-1,2,4-triazol-5-yl]acetic acid | 929339-46-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[3-(propan-2-yl)-1H-1,2,4-triazol-5-yl]acetic acid
• 英文别名: 2-(3-propan-2-yl-1H-1,2,4-triazol-5-yl)acetic acid
• CAS: 929339-46-8
• 化学式: C₇H₁₁N₃O₂
• 分子量: 169.18
• InChiKey: HGZUYYDHNDOCLA-UHFFFAOYSA-N

物化性质

• 沸点：
  417.1±28.0 °C(Predicted)
• 密度：
  1.284±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  78.9
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• THERAPEUTIC PIPERAZINES
  申请人：DART NEUROSCIENCE (CAYMAN) LTD.

  公开号：US20150087645A1

  公开（公告）日：2015-03-26

  The invention includes a compound of formula I: wherein R 1 , Y, A, n, R 4 and Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function and/or treating cognitive disorders or impairment, traumatic and/or ischemic injuries of the central and peripheral nervous system and/or psychiatric disorders in animals, especially humans.

  本发明涉及一种I式化合物：其中R1，Y，A，n，R4和Z具有以下任一数值，以及这些化合物的盐，包含这些化合物的组合物和包括这些化合物的治疗方法。这些化合物是PDE4功能的抑制剂，可用于改善动物（尤其是人类）的认知功能和/或治疗认知障碍或损伤、中枢和外周神经系统的创伤和/或缺血性损伤以及/或精神障碍。
• US8927546B2
  申请人：——

  公开号：US8927546B2

  公开（公告）日：2015-01-06
• US9624200B2
  申请人：——

  公开号：US9624200B2

  公开（公告）日：2017-04-18
• [EN] THERAPEUTIC PIPERAZINES<br/>[FR] PIPÉRAZINES THÉRAPEUTIQUES
  申请人：HELICON THERAPEUTICS INC

  公开号：WO2012040258A2

  公开（公告）日：2012-03-29

  The invention includes a compound of formula I... wherein R1, Y, A, n, R4 and Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function and/or treating cognitive disorders or impariment, traumatic and/or ischemic injuries of the central and peripheral nervous system and/or psychiatric disorders in animals, especially humans.